- 1、本文档共22页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
在体干细胞生物显像和心肌修复
* * Typical T1 weigted MR images of pelleted cells labeled with different concentration of Mn are shown at the top row. As the concentration of Mn increases, SI form the pellet increases as well. Second row shows that serial bioluminescence imaging of the hESC-luc+ activity with the same labeled with different concentration of MnCl2. * Reduction of SI difference by 26% (SI 727±139 vs. 379±248, n = 4) with addition of 250 uM verapamil and increase of SI difference by 30% (SI difference 727±139 vs 1220±317, n = 4) with addition of 5 uM (s)-(-)-Bay K8644, both in 0.1 mM MnCl2 solution. * * Before proceeding, I wanted to breifly review reporter gene based cell imaging. The concept is an expansion of established report gene techniques, where we start with the reporter gene DNA. In this case coding for luciferase, and introduce it into the cell to be tracked. The cell, as long as it is alive, will transplate this into the reporter protein. When we need to image the cell, a probe is injected into the animal, in this case luciferein. This then interacts with our report protein to yield a detectable signal. * * * * * * * * In Vivo Cellular and Molecular MRI of Embryonic Stem Cell Survival and Proliferation Phillip C. Yang, MD Assistant Professor Division of Cardiovascular Medicine Stanford University (No disclosure or conflict of interest) GREAT WALL INTERNATIONAL CONGRESS OF CARDIOLOGY BEIJING, CHINA 2008 I. Stem Cell Therapy: Congestive Heart Failure Coronary artery disease: #1 killer in the United States 1.1 million new or recurrent MI and 500,000 deaths per year Improved acute MI therapy shift in the landscape Congestive heart failure: #1 cause of hospital admissions in the US Prevalence: 5 million patients Incidence: 300,000 patients/year Advanced therapy: 5-year survival ~50% Heart transplant: 1,000 pt/year Recent stem cell research: alternative therapeutic option? II. Evaluation of Cell Therapy Clinical trials: modest, temporary improvement in LVEF
文档评论(0)